Theraworx Relief label update keeps muscle cramp claims in the homeopathic OTC lane
DailyMed’s updated label for THERAWORX RELIEF FOR MUSCLE CRAMPS ROLL ON places the product squarely in the familiar space of over-the-counter symptom relief while also making its regulatory status impossible to ignore. The formulation is listed as magnesium sulfate, unspecified form, delivered as a topical aerosol foam, with the label identifying the product as an unapproved homeopathic OTC drug. The practical signal for clinicians is straightforward: this is a consumer-facing muscle cramp product marketed for external use, not an FDA-evaluated therapy for a defined neuromuscular disorder.
The updated entry was published October 8, 2026, with the current package information showing an NDC code of 61594-025-00 and packaging in a 74 mL bottle. AVADIM HOLDINGS, INC. is listed as both labeler and registrant. The product’s active ingredient is described as magnesium sulfate, also referenced in the label as Magnesia sulphurica 6X 0.05% HPUS. That homeopathic designation matters because it frames the product’s intended identity and the level of evidentiary support attached to it. FDA’s disclaimer in the label is unambiguous: the product has not been evaluated for safety or efficacy, and FDA is not aware of scientific evidence supporting homeopathy as effective.
For a patient presenting with muscle cramping, the label’s claims are narrow and specific. The stated purpose is muscle cramp and soreness relief. The use statements go further, saying it helps prevent muscle cramps and spasms, helps release muscle tightness, and helps relieve muscle soreness. Those claims align with the way consumers commonly seek out topical products after exercise, prolonged standing, nocturnal leg cramps, or nonspecific muscular tightness. The biological plausibility, however, is not established by the label itself, and the label does not provide clinical trial data, comparative outcomes, or mechanistic evidence.
A single sentence captures the regulatory center of gravity here: this product remains an unapproved homeopathic OTC preparation, not an FDA-reviewed treatment for cramp prevention.
The topical route is important because it limits the product’s intended exposure to the skin. Directions instruct users to shake well, roll a thin layer onto each affected muscle group, allow it to air dry, and repeat as needed, with the label stating it is safe to use daily. External use is emphasized repeatedly. The warning language is equally direct: avoid eye contact, store between 32ºF and 120ºF, use only as directed, and do not ingest. If eye contact occurs, the label advises rinsing thoroughly with water. If swallowed, it instructs users to seek medical help or contact Poison Control right away.
Those instructions reflect the everyday realities of OTC topical products more than they do formal therapeutics. The intended bedside implication is simple: use this as a skin-applied symptomatic product, not as an oral supplement, not as a substitute for evaluation of recurrent cramps, and not as a treatment for unexplained neuromuscular symptoms. Muscle cramps can arise from dehydration, electrolyte abnormalities, medication effects, peripheral nerve issues, vascular disease, exercise-related muscle fatigue, or systemic illness. A topical roll-on can sit on top of that differential only as a comfort measure; it does not replace diagnostic workup when the pattern is persistent, severe, or atypical.
Pregnancy and breastfeeding precautions are included as well. The label advises pregnant or breastfeeding users to ask a health professional before use. It also says to keep the product out of reach of children. Those points are standard on many OTC products, but they are especially relevant when a product is sold in a form that resembles a cosmetic roll-on or foam rather than a conventional medication bottle. Packaging can influence how casually families handle storage and use, which makes the warnings more than a regulatory formality.
Several inactive ingredients may be relevant to tolerability and product experience rather than efficacy. The formulation includes allantoin, aloe vera leaf extract and juice, water, benzyl alcohol, citric acid, cocamidopropyl betaine, colloidal silver, glycerin, lauryl glucoside, fragrance, PEG/PPG-4/12 dimethicone, potassium sorbate, sodium benzoate, tetrasodium EDTA, tocopheryl acetate, xanthan gum, and yeast extract. In practice, those ingredients can affect texture, drying time, scent, and skin feel. They also introduce the possibility of skin irritation or sensitivity in individuals with reactive skin, even when the active ingredient itself is not absorbed systemically to any meaningful extent.
The label does not describe adverse event rates, comparative effectiveness, or any controlled trial program. It also does not provide outcome data that would allow a clinician to compare this product against massage, hydration, stretching, correction of underlying electrolyte disturbances, or other standard approaches to cramp management. For that reason, the label functions more as a regulatory and consumer-safety document than as evidence of therapeutic benefit. In outpatient practice, that distinction is not academic. Patients often arrive with a shelf of OTC products that promise relief from cramps, and the first clinical task is to separate symptom management from the cause of the symptom.
An additional line in the label deserves plain reading: “unapproved homeopathic.” In a field crowded with products that trade on patient frustration with recurrent cramps, that phrasing signals the absence of conventional FDA approval and the absence of a label-based evidence package for efficacy. Clinicians counseling patients about nocturnal cramps, post-exercise soreness, or generalized muscle tightness should treat the product as a self-care option with uncertain benefit, not as a disease-modifying intervention.
For patients who use it, the label’s own safety boundaries should remain front and center. Avoid the eyes. Do not swallow it. Store it within the listed temperature range. Seek medical attention if unintended effects occur. If cramps are recurrent, focal, unilateral, associated with weakness, or accompanied by swelling, numbness, or systemic symptoms, the problem belongs in a diagnostic framework rather than a product label. The label update does not change that clinical fact; it simply clarifies the product’s ingredients, warnings, and homeopathic status more visibly for consumers and prescribers alike.